Nanologica has received a supplementary order for the company’s silica-based purification media NLAB Saga® from a customer in the US who placed an initial order of approximately SEK 1.3 million in June. The customer is a manufacturer of peptide drugs and the order relates to evaluation of NLAB Saga® on a production scale.
In June, Nanologica received a first order from this customer in the US for evaluation of the company’s silica on a production scale. The customer’s evaluation is based on NLAB Saga® from different batches, which is why the initial order is now being completed. The order value is USD 283,400, which corresponds to approximately SEK 2.7 million at today’s exchange rate.
“The customer wants to evaluate NLAB Saga® from different batches, which is a clear indication that it is an evaluation with the aim of including our product in their production. The fact that our production is now stable and that we can thus deliver according to the customer’s wishes is pivotal for us to now be able to acknowledge this order,” Nanologica’s CEO Andreas Bhagwani comments.
The order is expected to be delivered in the fourth quarter.